Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Transplant Proc. Author manuscript; available in PMC 2010 December 21.
Published in final edited form as:
Transplant Proc. 1993 February; 25(1 Pt 1): 647–648.
PMCID: PMC3005710

Long-Term Survival of Heart and Liver Xenografts With Splenectomy and FK 506


We have reported that while hamster-to-rat liver xenograft survival is prolonged by FK 506, hamster hearts undergo humoral rejection under this immunosuppressant.1 Because the spleen has been shown to be one of the main sources of xenoantibodies,2,3 and in vivo experiments have demonstrated that splenectomy (Spx) is able to increase the efficacy of various immunosuppressive agents after xenotransplantation,46 we combined Spx with FK 506 to test whether survival of the intractable cardiac xenografts is prolonged, and of liver xenografts improved.


Lewis rats (250 to 280 g) and Golden Syrian hamsters (120 to 180 g) were used as recipients and donors, respectively. Heterotopic heart transplantation (HTx) was performed according to the method of Ono and Lindsey. while orthotopic liver transplantation (OLT) was performed according to the cuff technique. Splenectomy (Spx) was performed at the end of the transplant operation. The animals were divided in 12 groups, as shown in the Table 1.

Table 1
Survival of Hamster Cardiac and Liver Xenografts in Lewis Rat Recipients

A complement-dependent cytotoxicity test (CDC) was used serially to detect, in the recipient's serum, the amount of antihamster antibodies following heart and liver transplantation. Grafts of different groups were studied with light microscopy to create a relationship between the immunosuppressive therapy and the presence of rejection. At 100 days after transplantation, two animals in group 6 received intravenously 0.5 mL of serum taken from a group 1 rat at the time of rejection.


Table 1 shows xenograft survival. Among the animals that received heart transplantation, the best results were achieved with the combination of Spx and FK 506 2 mg/kg/d (group 6). In this group, all grafts survived beyond 100 days. The therapy with FK 506 1 mg/kg/d + Spx was effective in only two animals. Spx or FK 506 alone, even at high doses, did not significantly prolong the survival of the transplanted hearts. Among the animals that received liver transplantation, the best results were obtained with Spx + FK 506 1 mg/kg/d (group 11). Group 12, that received Spx + 2 mg/kg/d of FK 506, showed poorer results than group 11 and the groups that received FK 506 alone. In groups 8, 9, 11, and 12, all animals that died had severe jaundice and biliary dilatation at autopsy. In these cases, the histological study showed important biliary proliferation without signs of rejection. Heterophilic antibody production after cardiac xenografting was completely suppressed in group 6 (combined treatment). The recipients of the other groups showed peaks of antibody titers around the third postoperative day (range 1:8 to 1:512). In contrast, all animals that underwent liver transplantation developed high titers of cytotoxic antibodies around the seventh postoperative day (range 1:512 to 1:8182). Lower titers were found in the group treated with Spx and 1 mg/kg/d of FK 506 (1:128). Cytotoxicity in the serum of long-term survival liver recipients became negative by 3 to 4 weeks, regardless of the treatment. Long-term surviving cardiac xenografts which received hyperimmune antihamster serum underwent hyperacute rejection 3 minutes after injection.


Splenectomy seems to have a different impact after liver or heart xenotransplantation. While after heart xenografting, Spx + FK 506 2 mg/kg/d resulted in long-term graft survival in all recipients, confirming Carobbi's experiments,7 with the same therapy the percentage of long-term surviving liver xenografts was zero. The best protocol of immunosuppression for liver xenografts proved to be Spx + 1 mg/kg/d FK 506. However, even with this therapy, 100-day recipient survival was increased to only 50%. In both liver and heart xenotransplantation, there was a correlation between the presence of cytotoxicity in the serum of xenograft recipients and graft survival. Absence of cytotoxicity resulted in long-term survival. In contrast, high cytotoxic activity in the recipient sera meant rejection in the heart recipients—but only hepatic damage in the liver recipients. In fact, liver xenograft recipients that died while under treatment had severe jaundice with biliary dilatation. The histological findings of the liver grafts showed severe biliary proliferation, without signs of active rejection. According with these results, it seems possible to correlate the failure of the liver grafts to the damage induced by the first humoral attack of the natural and induced antibodies, mainly focalized in the biliary tract.8 This is in agreement with the observation that, after liver xenotransplantation, when FK 506 is combined with a drug that effectively prevents antibody production (antiproliferative drugs), we have never observed a hepatic failure with the characteristics described above.9

Paradoxically, after liver xenotransplantation, the animals receiving Spx + FK 506 2 mg/kg/d had higher mortality than the other groups. One explanation could be that high levels of FK 506 present in these rats increase the production of IL-10,10 a potent growth and differentiation factor for activated T-independent B lymphocytes.11

The hyperacute rejection of long-term surviving cardiac xenografts after injection with hyperimmune serum indicates that the vascular endothelium of the graft remains susceptible to humoral injury.

The liver seems to be more antigenic than the heart, as indicated by the huge splenomegaly,4 the massive splenic lymphocyte proliferation,2 and the very high cytotoxic titer observed after liver xenotransplantation. This would explain the slight improvement in survival of liver xenograft recipients. In conclusion, Spx + FK 506 can overcome the antibody barrier in the hamster-to-rat cardiac xenograft model with excellent graft survival.


1. Valdivia LA, Fung JJ, Demetris AJ, et al. Transplant Proc. 1991;23:3269. [PMC free article] [PubMed]
2. Langer A, Valdivia LA, Murase N, et al. Am J Pathol. (in press)
3. Valdivia LA, Monden M, Gotoh M, et al. Transplant Proc. 1988;20:329. [PubMed]
4. Valdivia LA, Monden M, Gotoh M, et al. Transplantation. 1987;44:759. [PubMed]
5. Wang J, Morris RE. Transplant Proc. 1991;23:699. [PubMed]
6. Yamaguchi Y, Halperin EC, Harland RC, et al. Transplantation. 1990;49:13. [PubMed]
7. Carobbi A, Arenada D, Parseles T, et al. Transplant Proc. 1991;23:549. [PubMed]
8. Demetris AJ, Murase N, Nakamura K, et al. Sem Liver Dis. 1992;12:51. [PubMed]
9. Murase N, Starzl TE, Demetris AJ, et al. Transplantation. (in press)
10. Thai NL, Valdivia LA, Celli S, et al. Transplant Roc. (in press)
11. Rousset F, Garcia E, Defrance T, et al. Immunology. 1992;89:1890. [PubMed]